CVM GFI #267 Biomarkers and Surrogate Endpoints in Clinical Studies to Support Effectiveness of New Animal Drugs
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
October 6, 2021
October 5, 2021
017aa044-c960-4f4a-b6e9-4aed194af7c4
Related Documents
CVM GFI #265 Use of Data from Foreign Investigational Studies to Support Effectiveness of New Animal Drugs
Guidance DocumentOctober 6, 2021Center for Veterinary Medicine
CVM GFI #268 Adaptive and Other Innovative Designs for Effectiveness Studies of New Animal Drugs
Guidance DocumentOctober 6, 2021Center for Veterinary Medicine
CVM GFI #255 Elemental Impurities in Animal Drug Products Questions and Answers
Guidance DocumentNovember 23, 2020Center for Veterinary Medicine
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox